KYTX Kyverna Therapeutics Inc.
Price (delayed)
$2.15
Market cap
$92.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.33
Enterprise value
$3.98M
We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from
Highlights
Kyverna Therapeutics's EPS has soared by 96% YoY and by 89% from the previous quarter
Kyverna Therapeutics's debt has decreased by 10% QoQ and by 9% YoY
Kyverna Therapeutics's quick ratio has soared by 190% YoY but it has decreased by 18% from the previous quarter
The net income has dropped by 111% year-on-year and by 15% since the previous quarter
KYTX's equity is down by 12% since the previous quarter
Key stats
What are the main financial stats of KYTX
Market
Valuations
Earnings
Shares outstanding
43.21M
Market cap
$92.91M
Enterprise value
$3.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.6M
Net income
-$127.48M
EBIT
-$127.34M
EBITDA
-$122.66M
Free cash flow
-$116.46M
Per share
Balance sheet
Liquidity
EPS
-$3.33
EPS diluted
-$3.33
Free cash flow per share
-$3.04
Book value per share
$6.18
Revenue per share
$0
TBVPS
$7.95
Total assets
$304.65M
Total liabilities
$38.06M
Debt
$8.24M
Equity
$266.59M
Working capital
$256.85M
Debt to equity
0.03
Current ratio
8.61
Quick ratio
8.49
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.5%
Return on equity
-40.3%
Return on invested capital
-66.5%
Return on capital employed
-47%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYTX stock price
How has the Kyverna Therapeutics stock price performed over time
Intraday
8.59%
1 week
-14%
1 month
-24.3%
1 year
-90.61%
YTD
-42.51%
QTD
11.4%
Financial performance
How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.6M
Net income
-$127.48M
Gross margin
N/A
Net margin
N/A
KYTX's operating income has shrunk by 129% YoY and by 16% QoQ
The net income has dropped by 111% year-on-year and by 15% since the previous quarter
Growth
What is Kyverna Therapeutics's growth rate over time
Valuation
What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has soared by 96% YoY and by 89% from the previous quarter
The price to book (P/B) is 75% lower than the last 4 quarters average of 1.3
KYTX's equity is down by 12% since the previous quarter
Efficiency
How efficient is Kyverna Therapeutics business performance
KYTX's ROIC has soared by 69% YoY and by 8% QoQ
The company's return on assets has surged by 57% YoY and by 3.7% QoQ
The company's return on equity rose by 21% QoQ
Dividends
What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYTX.
Financial health
How did Kyverna Therapeutics financials performed over time
Kyverna Therapeutics's quick ratio has soared by 190% YoY but it has decreased by 18% from the previous quarter
The current ratio has soared by 182% YoY but it has contracted by 18% from the previous quarter
Kyverna Therapeutics's debt is 97% lower than its equity
KYTX's debt to equity has soared by 143% YoY
KYTX's equity is down by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.